Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.

Chengfang Li(Shihezi University), Feng Li(Bengbu Medical College), Lijuan Pang(Guangdong Medical College), Yaoyuan Shen(Shihezi University), Wei Liu(Second People’s Hospital of Yibin), Chunxia Liu(Inner Mongolia Agricultural University), Wei-Hua Liang(Shihezi University), Hongchao Dong(Shihezi University), Bingcheng Li(Shihezi University), Xiaobin Cui(Tongji Hospital)

PubMed

January 1, 2014

Cited by 9

Related Papers

Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

|Nature|2019|982

Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells

|Nature Medicine|2012|634

Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization

|Journal of Neuroinflammation|2020|609

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Camelid genomes reveal evolution and adaptation to desert environments

|Nature Communications|2014|317